EGFR and KRAS, the types of oncogenic drivers in NSCLC, can activate the PI3K/AKT/mTOR pathway, which enhances cancer cell proliferation, metabolism, and survival [184]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.